INTRODUCTION AND OBJECTIVES:
The selective arterial clamping (SAC) technique was developed as an alternative to total arterial clamping (TAC) in an effort to improve renal functional outcomes after partial nephrectomy. The aim of this study was to evaluate whether the selective SAC technique during robot-assisted partial nephrectomy (RAPN) provides any renal functional benefit over TAC in patients with >1 year of follow-up.
METHODS: Our study cohort comprised 208 patients without impaired renal function who underwent SAC (n[55) or TAC (n[153) during RAPN performed by a single surgeon at Kobe University Hospital during the period of 2011-2016. To minimize the selection bias between the two clamp methods, both RENAL nephrometry score and warm ischemia time (WIT) were adjusted by 1:1 propensity score matching.
RESULTS: After propensity score matching, 55 patients were included in each clamping technique group. SAC and TAC RPN patients were compared with no significant differences in age, gender, surgical approach (trans-or retroperitoneal), tumor size, baseline estimated glomerular filtration rate (eGFR), American Society of Anesthesiologists (ASA) physical status or Karnofsky performance status. The mean WIT was 19.1 min in the SAC group and 19.6 min in the TAC group. The mean nephrometry score was 6.8 in both groups. The SAC group had a greater mean blood loss volume (58.5 vs 24.5 ml; p[0.048) than the TAC group. No significant differences were found between the groups regarding the positive surgical margin (0%), overall complication rate (7.2 vs 5.4%; p[0.779) or trifecta achievement (85.5 vs 90.1%; p[0.556). Regarding postoperative renal function, the SAC group had significantly less deterioration at 1 week after surgery (percentage reduction in eGFR -9.7 vs -16.7%; p[0.002), but this outcome was not observed after 1 month (9.4 vs 11.1%; p[0.356) to over 1 year (10.8 vs 12.1%; p[0.441) . Of note, SAC was more beneficial for patients with a high CKD stage (>G3) to reduce the decrease in eGFR after surgery (n[18, each group).
CONCLUSIONS: Our data suggested that the SAC technique results in superior short-term renal functional outcomes compared with TAC; however, after 1 postoperative month, there were no significant differences regarding the renal functional outcome when the mean WIT was less than 20 minutes in our series. Furthermore, the SAC technique may be beneficial for patients with a high CKD stage in order to preserve renal function. (NSS) showed no better renal function at 6 months than those who received placebo. Despite these results, some have suggested that patients with comorbidities, including lower pre-operative estimated glomerular filtration rate (eGFR), may still derive some benefit. We sought to address this hypothesis by reanalyzing trial data and long-term renal function outcomes.
METHODS: Between 2012-2015, 199 patients undergoing NSS with eGFR !45 mL/min/1.73 m 2 were randomized 1:1 to receive mannitol or normal saline within 30 minutes of renal artery occlusion. The original endpoint was to assess differences in eGFR at 6 months. In this analysis, follow-up was extended to 3 years. Using ANCOVA, we assessed whether the effect of mannitol on post-operative eGFR was modified by pre-operative eGFR or other patient and surgical factors.
RESULTS: 134 (67%) trial patients had eGFR available at 3 years. Patients missing from the follow-up analysis were not significantly different from the study population. Median pre-operative and 3-year post-operative eGFR in the mannitol arm were 86 and 77 mL/min/1.73m 2 respectively vs. 89 and 79 ml/min/1.73m
2 . There was no significant difference between groups (mean GFR difference 1.4; 95% CI -2.6, 5.3; p[0.5). At both 6 months and 3 years, the effect of mannitol was not significantly modified by patient or surgical factors including pre-operative eGFR (p[0.3), coronary artery disease (0.15), diabetes (0.9), surgical approach (0.14), ischemia time (0.3), and tumor size (0.09). There was a small non-significant trend favoring mannitol in patients with higher pre-operative eGFR (Figure 1 ). There was also a non-significant trend favoring mannitol in larger tumors at 6 months; this relationship was reversed at 3 years (favored in smaller tumors), suggesting a random variation rather than a true effect.
CONCLUSIONS: Intra-operative use of mannitol does not improve either short-or long-term renal function in patients undergoing NSS. There is no evidence of effect modification by comorbidities, including lower pre-operative eGFR, supporting the validity of the original trial conclusions within the spectrum of diseases of this patient population.
